Team

Lori Steelman joined Atavistik Bio as Vice President, Clinical Science in March 2026. She brings more than 25 years of experience in drug development spanning translational research through global regulatory approvals in oncology indications. At Atavistik Bio, she oversees clinical science, data management, and pharmacovigilance. Most recently, she served as Global Head of Late-Stage Clinical Scientists at Servier Pharmaceuticals, where she led a team across the U.S., Europe, and China. She served as the clinical science lead for vorasidenib (VORANIGO®) which received worldwide marketing approval for Grade 2 IDH-mutant gliomas. Prior to Servier, Lori held clinical science roles of increasing responsibility at Agios Pharmaceuticals, Infinity Pharmaceuticals, and AVEO Pharmaceuticals, contributing to the design, execution, and regulatory strategy from Phase 1 through pivotal registration trials.

Lori received her MS in Genetics from Thomas Jefferson University and  her BS in Biotechnology from the University of Delaware.